Efficacy And Safety Of Catheter-Based Renal Sympathetic Denervation In Treatment Of Chronic Heart Failure

Chao Li,Li Wang,Zhuqing Li,Feng Zhang,Xin Chen,Chengzhi Lu
2018-01-01
Abstract:Background and aim: Chronic heart failure (CHF) is a disease with a relatively unsatisfactory prognosis. Sympathetic overactivity is an important factor for occurrence and development of heart failure. Catheter-based renal sympathetic denervation (RDN) can specifically remove renal afferent and efferent nerves, thus, reducing function of the sympathetic nervous system. This study aimed to investigate the efficacy and safety of catheter-based RDN in treatment of CHF. Methods: Twenty-four CHF patients were randomly divided into a control group (12 cases) and RDN group (12 cases). All patients received anti-heart failure therapy using drugs with maximum tolerated doses. In addition, the RDN group received catheter-based RDN based on medication. After 6 months of treatment, overall treatment efficacy was observed. Cardiac function indexes, heart rate variability indexes, and safety indexes were determined. Results: After treatment, overall treatment efficacy in the RDN group was significantly better than in the control group (P < 0.05). Left ventricular end-systolic dimension and left ventricular end-diastolic dimension in the RDN group were significantly lower than those in the control group (P < 0.05). Plasma N-terminal-pro-B-type natriuretic peptide levels and 6-minute walk distances in the RDN group were significantly higher than those in the control group (P < 0.05). In addition, standard deviation of NN intervals, standard deviation of average normal sinus R-R intervals for all 5-min segments, root mean square of successive normal sinus R-R interval difference, and percentage of successive normal sinus R-R interval longer than 50 minutes in RDN group were significantly higher than those in the control group (P < 0.05). During and after treatment, there were no obvious complications in the two groups. Conclusion: Catheter-based RDN can obviously improve cardiac function and heart rate variability for CHF patients. It is an effective and safe method for the treatment of CHF.
What problem does this paper attempt to address?